Abstract: The present disclosure provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ?90%; wherein R1, R2, X and n are as defined herein. The present disclosure further provides use of the composition according to the present disclosure for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a Coronavirus which comprises administering the composition of the present disclosure to a subject. The composition of the present disclosure comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ?90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present disclosure provides a crystal form comprising a compound of Formula (I) and fumaric acid, wherein the crystal form satisfies at least one of the following conditions: (1) a particle size D90 of the active pharmaceutical ingredient ranges from about 5 ?m to about 60 ?m; and (2) a particle size D50 of the active pharmaceutical ingredient does not exceed about 30 ?m; a pharmaceutical composition containing the crystal form, and a method for treating coronavirus-induced diseases by using the crystal form. The crystal form of the present disclosure enables the pharmaceutical composition containing the crystal form to have advantages such as a higher dissolution rate, a higher dissolution, and the like.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ? 90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: The present invention discloses a process for improving the fluidity of palbociclib isethionate and a composition, and belongs to the field of pharmaceutical preparations. The process includes a step of conducting granulation on palbociclib isethionate and pharmaceutically acceptable auxiliary materials to obtain granules with a tap density of 0.55-0.72 g/mL and an angle of repose of less than or equal to 44°. According to the process of the present invention, the palbociclib isethionate composition has good granular fluidity during filling of capsules, and prepared palbociclib isethionate capsules have uniform content, good stability and controllable quality. A preparation method is convenient to operate and easy to understand and adjust, and has good controllability in expanded production.

Abstract: The present disclosure provides an active pharmaceutical ingredient containing a crystal form including a compound of Formula (I) and fumaric acid. An X-ray powder diffraction pattern of the crystal form obtained by using Cu-K? radiation includes at least three peaks selected from the group consisting of 10.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?; a particle size D90 of the active pharmaceutical ingredient is smaller than or equal to 20 ?m, and a particle size D50 of the active pharmaceutical ingredient is smaller than or equal to 10 ?m.

Abstract: The present disclosure provides a crystal form of a compound and fumaric acid, an active pharmaceutical ingredient and a pharmaceutical composition containing the same, and a method for treating coronavirus-induced diseases a using the same. In particular, the crystal form of the present disclosure comprises the compound of Formula (I) and fumaric acid, and the X-ray powder diffraction pattern of the crystal form obtained using Cu-K? radiation includes at least three peaks selected from the group consisting of: 0.94°±0.2° 2?, 19.06°±0.2° 2?, 23.50°±0.2° 2?, and 24.66°±0.2° 2?. The crystal form of the present disclosure has a high purity, good stability, and a high melting point.